Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation
Open Access
- 30 December 2023
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (4) , 294-296
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in JapanThe Journal of Dermatology, 2022
- Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialDermatology and Therapy, 2022
- EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with TralokinumabJournal of Investigative Dermatology, 2022
- Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*British Journal of Dermatology, 2021
- The IL-4, IL-13 and IL-31 pathways in atopic dermatitisExpert Review of Clinical Immunology, 2021
- What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?Seminars in Immunopathology, 2021
- Biomarkers in atopic dermatitis—a review on behalf of the International Eczema CouncilJournal of Allergy and Clinical Immunology, 2021
- EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkersAllergy, 2020
- Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2002